Milestone Pharmaceuticals (NASDAQ:MIST) Cut to Hold at Zacks Research

Zacks Research lowered shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a strong-buy rating to a hold rating in a research note published on Tuesday,Zacks.com reports.

Several other research firms have also recently issued reports on MIST. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, Wells Fargo & Company lifted their price objective on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Milestone Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.00.

Milestone Pharmaceuticals Stock Down 0.6%

Shares of Milestone Pharmaceuticals stock opened at $1.72 on Tuesday. The company has a 50-day simple moving average of $1.92 and a two-hundred day simple moving average of $2.00. The stock has a market capitalization of $146.49 million, a PE ratio of -2.10 and a beta of 0.46. Milestone Pharmaceuticals has a 52-week low of $0.63 and a 52-week high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Insider Transactions at Milestone Pharmaceuticals

In other Milestone Pharmaceuticals news, insider Lorenz Muller sold 53,566 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $2.32, for a total value of $124,273.12. Following the transaction, the insider directly owned 196,486 shares of the company’s stock, valued at approximately $455,847.52. This trade represents a 21.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Bharucha sold 58,007 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $2.32, for a total value of $134,576.24. Following the sale, the insider owned 91,993 shares of the company’s stock, valued at approximately $213,423.76. This represents a 38.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 416,327 shares of company stock worth $935,458. 19.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Simplify Asset Management Inc. grew its position in Milestone Pharmaceuticals by 16.5% during the second quarter. Simplify Asset Management Inc. now owns 990,000 shares of the company’s stock valued at $1,921,000 after buying an additional 140,000 shares during the period. Creative Planning boosted its stake in shares of Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after acquiring an additional 10,000 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Milestone Pharmaceuticals by 209.5% during the 2nd quarter. XTX Topco Ltd now owns 160,963 shares of the company’s stock worth $312,000 after acquiring an additional 108,959 shares during the last quarter. Raymond James Financial Inc. grew its position in shares of Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after acquiring an additional 10,000 shares during the period. Finally, Valeo Financial Advisors LLC increased its stake in shares of Milestone Pharmaceuticals by 553.5% in the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after purchasing an additional 110,699 shares in the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.